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a  b  s  t  r  a  c  t
P-glycoprotein  (Pgp)  and  XIAP  co-expression  has  been  discussed  in  the  process  of  the  acquisition  of
multidrug  resistance  (MDR)  in  cancer.  Here,  we  evaluated  XIAP  and  Pgp  expression  in  chronic  myeloid
leukemia  (CML)  samples,  showing  a positive  correlation  between  them.  Furthermore,  we evaluated  the
effects  of  imatinib  in  XIAP  and  Pgp  expression  using  CML  cell  lines  K562  (Pgp−)  and  K562-Lucena  (Pgp+).
Imatinib increased  XIAP  and  Pgp  expression  in  K562-Lucena  cells,  while  in K562  cells  a downregulation
of  these  proteins  was  observed,  suggesting  that  imatinib  induces  an  increment  of  MDR  phenotype  of  CMLeywords:
hronic myeloid leukemia
matinib
-glycoprotein
IAP
urvivin
cells  that  previously  exhibit  high  levels  of  Pgp/XIAP  co-expression.
© 2013 Elsevier Ltd. All rights reserved.ultidrug resistance
. Introduction
Imatinib mesylate (imatinib) in chronic myeloid leukemia (CML)
reatment has profoundly changed the management of this disease,
nducing complete cytogenetic response in up to 90% of patients
1]. However, a signiﬁcant percentage of patients fail in imatinib
reatment due to drug resistance [2].
Among the mechanisms of imatinib resistance that have already
een described, the overexpression of drug transporter genes such
s MDR1 that encodes the efﬂux pump P-glycoprotein (Pgp) has
een emerged as an important factor [3,4].
Other mechanism of drug resistance occurs through overex-
ression of antiapoptotic proteins called inhibitor of apoptosis
roteins (IAPs). In fact, IAPs overexpression has been reported
s a marker of poor prognosis in several cancers [5]. Survivin, a
Abbreviations: CML, chronic myeloid leukemia; Pgp, P-glycoprotein; MDR,
ultidrug resistance; IAPs, inhibitor of apoptosis proteins; RFI, ratio of mean of ﬂu-
rescence intensity; MFI, mean of ﬂuorescence intensity; Rho-123, rhodamine-123;
SA, cyclosporin A; VRP, verapamil; IC50, concentration achieving 50% inhibition of
ell growth.
∗ Corresponding author at: Laboratório de Hemato-Oncologia Celular e Molecular,
nstituto Nacional de Câncer, Prac¸ a Cruz Vermelha 23, 6◦ andar, Centro, CEP 20230-
30, Rio de Janeiro, RJ, Brazil. Tel.: +55 21 32071198; fax: +55 21 32071808.
E-mail addresses: rcmaia@inca.gov.br, rcm@unisys.com.br (R.C. Maia).
145-2126/$ – see front matter ©  2013 Elsevier Ltd. All rights reserved.
ttp://dx.doi.org/10.1016/j.leukres.2013.06.014member of the IAPs family, is overexpressed in accelerated and
blastic phases of CML  [6,7] and is related to suboptimal clinical
response to imatinib [8]. The antiapoptotic role of XIAP, the most
potent member of the IAPs family, has been demonstrated in CML
cell line models [9–11]; however, it has not been well explored in
CML  samples yet.
Some reports have discussed the association between Pgp and
IAPs in the process of multidrug resistance (MDR) in cancer. It was
demonstrated that XIAP and survivin contribute to an unfavorable
prognosis in association with Pgp overexpression in patients with
multiple myeloma [12]. Moreover, our group observed a signiﬁcant
correlation between Pgp and survivin in CML  samples from patients
previously treated, suggesting a contribution of these proteins in
the MDR  phenotype [13]. Reinforcing this correlation, members of
our group also veriﬁed that treatment of K562, a CML  cell line, with
high doses of vincristine, a Pgp substrate, induced a concomitant
overexpression of Pgp and survivin and it was  associated with a
low apoptotic index [14].
Based on those premises, the present work analyzed the expres-
sion of XIAP and Pgp in samples from CML  patients. Furthermore,
we evaluated the effects of imatinib in Pgp and XIAP expres-
sion and their association with drug resistance using K562 cell
line, which presents undetectable levels of Pgp protein expression
(Pgp−) and its derivative K562-Lucena (Lucena) that overexpresses
Pgp (Pgp+).
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. Materials and methods
.1. Patient samples
Cells from peripheral blood or bone marrow of 48 CML  patients were isolated
hrough density gradient centrifugation by Ficoll–Hypaque (Sigma–Aldrich). The
tudy was  performed in accordance with the Declaration of Helsinki and approved
y  the Institution Ethics Committee. The diagnosis of CML  was  based on standard
linical data and conﬁrmed by cytogenetics and molecular analysis. Patients’ char-
cteristics are summarized in Table 1. Patients analyzed at early chronic phase had
ot  been submitted to any treatment, except hydroxyurea, while those that were
nalyzed in late chronic phase showed resistance to drugs used for CML  treatment.
istinct prognostic groups were categorized as low, intermediate, and high risk as
eﬁned by Sokal risk score system [15].
.2. Cell lines
The human erythroblastoid CML  K562 cell line (Pgp−) and its vincristine-
esistant derivative Lucena (Pgp+) were cultured as previously described [16].
ucena cells were cultured with 60 nM vincristine (Tecnocris® , Zodiac). Before the
onduct of the experiments, Lucena cells were cultured without vincristine for 72 h.
.3. MTT  assay
Cell viability was  evaluated by a modiﬁed MTT  assay and performed as pre-
iously described [17]. K562 and Lucena cells (105 cells/mL) were treated with
matinib mesylate (Glivec® , Novartis Pharmaceuticals) for 24, 48, and 72 h, at a
nal concentration ranging from 0.5 to 10 M.  Absorbance at 492 nM was  mea-
ured with an ELISA reader (DTX 800 Multimode Detector from Beckman Coulter),
nd the percentage of cell viability was  assessed as: (absorbance of imatinib treated
ells/absorbance of untreated cells) × 100. The concentrations and experiments
ere done in triplicate.
.4. Apoptosis assay
Annexin V-FITC-based apoptosis measurements were performed according to
anufacturer’s instructions, as previously described [18], using Apoptosis Detection
it (Genzyme Corporation). 106 K562 or Lucena cells were treated with imatinib for
4 h and 48 h at concentrations of 0.5, 1.0, and 5.0 M in presence or absence of
erapamil (VRP) at 50 M.  Cyan ﬂow cytometer (Beckman Coulter) was used to
etect apoptosis, and data were analyzed using Summit v4.3 software (Dako).
.5. Detection of Pgp expression
Leukemic cells (5 × 105) from cell lines or CML  samples were stained with 5 L of
E-conjugated monoclonal antibody against Pgp (clone UIC2, Coulter) as previously
escribed [19]. Fluorescence was analyzed by ﬂow cytometry, and the results were
xpressed as the ratio of mean of ﬂuorescence intensity (RFI). The RFI was  obtained
y  dividing the mean of ﬂuorescence intensity (MFI) of cells incubated with anti-Pgp
y  the MFI  of cells without monoclonal antibodies [19].
.6. Determination of Pgp activity
Pgp activity was assayed in patients’ cells and in cell lines according to a pre-
ious study [19]. Cells (5 × 105) were incubated with 200 ng/mL rhodamine-123
Rho-123) plus 200 ng/mL cyclosporin A (CSA) (Atopica® , Novartis Pharmaceuticals)
or  45 min at room temperature. Cells were washed in ice cold PBS and incubated
ith CSA in dye-free medium for another 45 min  at room temperature, followed by
ow cytometry analysis. Cells without Rho-123 or CSA were used to evaluate cell
utoﬂuorescence. Results were expressed as the RFI obtained by dividing the MFI  of
ells incubated with Rho-123 and CSA by the MFI  of cells with Rho-123 alone after
ubtracting the MFI  representing the autoﬂuorescence.
To  determine the capability of imatinib to act as a substrate of Pgp, 1 M and
 M of imatinib were used to compare with CSA.
.7. Immunoblotting
XIAP, survivin and caspase-3 detections were performed as previously described
20]. After SDS-PAGE, proteins were transferred to Hybond-P membranes (GE
ealthcare). Blots were incubated with antibodies against XIAP or survivin (1:1000
ilution, R&D Systems), caspase-3 (1:500 dilution, BD Biosciences), or -actin
1:1000 dilution, Sigma–Aldrich) for 1 h in 5% non-fat dry milk TBS containing 0.2%
ween-20. Secondary antibodies comprised horseradish peroxidase (HRP)-labeled
nti-mouse or anti-rabbit antibodies (1:1000 dilution, GE Healthcare). Blots were
xposed to them for 1 h. Antibody complexes were visualized by the ECL detection
ystem (GE Healthcare), and band intensities were quantiﬁed using the VisionWorks
oftware. In CML  samples, the expression of XIAP was normalized with respect to
-actin.rch 37 (2013) 1350– 1358 1351
2.8. Analysis of MDR1, XIAP, and survivin gene expression in CML  cell lines
K562 and Lucena cell lines (2 × 105 cells/well) were cultured in 2000 l of RPMI
medium with 10% FBS for 24 h in the presence or absence of imatinib at 1.0 and
5.0  M.  Afterwards, the levels of MDR1, XIAP, and survivin mRNA expressions were
evaluated by real-time qRT-PCR, and performed as previously described [13].  XIAP,
survivin, MDR1, and -actin mRNAs were ampliﬁed by real-time qRT-PCR using
assay on demand probes (MDR1 [Hs01067802 m1], XIAP [Hs01597783 m1], sur-
vivin [Hs000153353 m1], -actin [Hs99999903 m1]; Applied Biosystems). -actin
was  used as a reference gene for all samples to normalize the Ct values for the target
gene. All experiments were carried out in the StepOneTM Real-Time PCR System
(Applied Biosystems).
2.9. Inhibition of XIAP expression by siRNA in CML  cell lines
K562 and Lucena cell lines were transfected with the Cell Line Nucleofactor®
kit V, program T-016 and 50 pmol of siRNA targeting XIAP with the fol-
lowing sequences: sense (5′GAAUCUUAAUAUUCGAAGUtt 3′) and antisense
(5′ACUUCGAAUAUUAAGAUUCcg 3′). Transfection and cell culture post-transfection
were performed according to manufacture’s instructions. After 24 h of transfection,
cells were treated with imatinib at 1 M and 5 M for more 24 h. A non-targeting
siRNA (Silencer® select negative control, Ambion, Applied Biosystems) was used as
control.
2.10. Statistical analysis
One-way analysis of variance (ANOVA) test was used to verify differences
between cell lines viability and apoptosis induction.
The Mann–Whitney U test or Kruskal–Wallis test was used for statistical com-
parisons of XIAP expressions between the subgroups of the cohort of patients. The
Spearman correlation test was used to correlate XIAP expression with other biolog-
ical parameters. Chi-square test was performed to evaluate the frequency of XIAP
and Pgp co-expression in CML  samples.
All  of the statistical analyses were done with the GraphPad Prism software pro-
gram (version 4). A p-value lower than 0.05 was considered to indicate statistical
signiﬁcance.
3. Results
3.1. XIAP expression and Pgp status in CML samples
To verify whether XIAP protein expression would be involved
in CML  evolution, we  analyzed its expression in 48 samples from
CML  patients and compared it with clinical parameters. Taking into
account all CML  samples, the relative XIAP expression varied from
0.11 to 8.08 (median = 1.17). Considering the median value of 1.17
as the cut-off point to segregate low (≤1.17) and high (>1.17) XIAP
expression, 24 samples (50%) showed high levels of XIAP expres-
sion. Analyzing the levels of XIAP expression according to CML
disease status (early chronic, late chronic, and accelerated/blastic
phases), we  veriﬁed that 16 of the 32 samples (50%) from patients at
early chronic phase exhibited XIAP overexpression, while 3 from 7
samples (42.8%) at late chronic phase and 5 from 9 samples (55.5%)
at accelerated/blastic phases demonstrated high levels of XIAP. Due
to the wide variation of XIAP expression among the groups, no
statistical difference in XIAP expression was observed among CML
disease statuses (p = 0.838) or Sokal risk groups (p = 0.925) (Table 1).
As some articles have found a positive correlation between IAPs
expression and MDR  phenotype, we concomitantly analyzed the
expression of Pgp in 38 out of 48 CML  samples by ﬂow cytome-
try. Pgp expression varied from 1.00 to 5.70 (median = 1.65) when
all samples were considered. Considering the median value of RFI
(1.65) as the cut-off point to segregate expression (≤1.65) and
overexpression (>1.65) levels of Pgp, 17 samples (44.7%) had Pgp
overexpression. Out of 26 samples from patients at early chronic
phase, 11 showed Pgp overexpression (42.3%), while 2 from 6 sam-
ples (33.3%) at late chronic phase and 4 from 6 samples (66.6%) at
accelerated/blastic phases overexpressed Pgp. Hence, the majority
of samples at advanced phases of CML  showed high levels of Pgp
expression. Moreover, analysis of the median of Pgp expression in
relation to CML  status showed that samples in accelerated/blastic
phases exhibited a higher median of Pgp expression (RFI = 2.22)
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Table 1
Demographic, clinical and biological characteristics of CML  patients.
Early chronic phase (n = 32) Late chronic phase (n = 7) Accelerated/blastic phases (n = 9) p value
Age median (range) 45.5 (9–81) 38 (28–65) 45 (26–67)
Gender
Male  15 5 8
Female 17 2 1
Sokal score 0.925
Low  14 5 3
Intermediate 8 1 2
High 9 1 2
MDR  phenotype (n = 26) (n = 6) (n = 6)
XIAP  expression median (range)a 1.17 (0.18–2.93) 1.05 (0.11–4.43) 1.24 (0.31–8.08) 0.838
P-glycoprotein expression median (range)b 1.65 (1.00–5.70) 1.29 (1.00–3.88) 2.22 (1.47–3.40) 0.252
P-glycoprotein activity median (range)c 1.20 (1.00–3.59) 1.27 (1.00–1.50) 1.14 (1.00–1.42) 0.942
a Relative XIAP expression in relation to -actin by Western blot.
rug re
P
a
c
a
r
p
(
o
(
e
(
c
w
c
F
C
t
rb Protein expression MIF.
c Rhodamine-123 efﬂux MIF; MIF  = mean of intensity ﬂuorescence. MDR = multid
-glycoprotein expression or P-glycoprotein activity among the groups.
s compared with patients at early (RFI = 1.65) or late (RFI = 1.29)
hronic phases; however, no statistical difference was observed
mong them (p = 0.252) (Table 1). In relation to Sokal risk, no cor-
elation was observed between Pgp expression and samples from
atients at low risk or intermediate/high risk groups (p = 0.251).
In relation to Pgp activity, the RFI ranged from 1.00 to 3.59
median = 1.20) (Table 1). Considering the median as the cut-
ff point to segregate low activity (RFI ≤ 1.20) and high activity
RFI > 1.20), 18 samples (47.4%) showed high activity of Pgp. Nev-
rtheless, Pgp activity was not related to CML  disease status
p = 0.942) or Sokal risk (p = 0.601).Interestingly, when the levels of XIAP and Pgp expressions were
orrelated, a signiﬁcant positive correlation (p = 0.026; r = 0.152)
as observed between these proteins (Fig. 1A). Considering the
ut-off points of 1.17 and 1.65 for XIAP and Pgp overexpressions,
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hodamine-123 (Rho-123) efﬂux assay. Spearman test was performed to determine corresistance. The Kruskal–Wallis test was performed to verify differences in XIAP and
respectively, 14 samples (36.8%) presented a high co-expression
(XIAPhigh/Pgphigh), while 4 (10.5%) samples were XIAPhigh/Pgplow,
6 samples (15.8%) were XIAPlow/Pgphigh, and 14 (36.8%) samples
presented low levels of co-expression (XIAPlow/Pgplow). Taking into
account these four groups of XIAP/Pgp expression, the Chi-square
statistical analysis demonstrated that there was  a signiﬁcant differ-
ence between XIAPhigh/Pgphigh and XIAPlow/Pgplow co-expression
(p = 0.003), suggesting a relationship between these proteins.
Despite that we observed a positive correlation between XIAP
and Pgp expressions, the expression of XIAP was  not correlated with
Pgp activity observed by Rho-123 efﬂux assay (Fig. 1B). Further-
more, Pgp expression was  not correlated with Pgp activity (Fig. 1C).
Although the high co-expression of XIAP and Pgp has not been
related to CML  phases or Sokal risk, probably due to the small
number of samples and their heterogeneity, this ﬁnding raised
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bsence of high levels of XIAP/Pgp co-expression against imatinib
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.2. Effect of imatinib on CML  cell lines viability
To investigate a possible differential response to imatinib in
ur Pgp overexpressing CML  cell line model (Lucena) in relation
o its parental cell line (K562), cells were treated with increasing
oncentrations of imatinib for 24, 48, and 72 h, and cell viability
as evaluated by MTT  assay. Both cell lines had their viability
ecreased after imatinib treatment. Concentrations of imatinib
bove 1 M showed no signiﬁcant difference in cell viability in
oth cell lines. Imatinib concentration achieving 50% inhibition of
ell growth (IC50) was approximately 1 M at 48 h in K562 and
ucena. However, Lucena cells were signiﬁcantly more resistant
han K562 when treated with imatinib at 0.5 M for 48 h (p = 0.030)
nd at 0.5 M (p = 0.041), 1.0 M (p = 0.031), 5.0 M (p = 0.049), and
0.0 M (p = 0.002) for 72 h (Fig. 2).
.3. Lucena cell line is resistant to apoptosis induced by imatinib
We  next investigated whether the reduction of cell viability
bserved by MTT  assay was due to imatinib induction of apopto-
is in CML  cell lines. As shown in Fig. 3A, imatinib was  able to
nduce apoptosis in both cell lines. However, Lucena showed to
e less sensitive to imatinib than K562 when treated with 5 M for
4 h (p = 0.025), 0.5 M (p = 0.03) for 48 h, and 0.5 M (p = 0.03) or
 M (p = 0.001) for 72 h, suggesting that Pgp overexpression might
onfer imatinib resistance.
The apoptotic effect of imatinib was also veriﬁed by caspase-3
ctivation. As observed in Fig. 3B, K562 had a more pronounced
aspase-3 activation when compared to Lucena cell line.
.4. Imatinib is a modulator of Pgp activity
To verify the capability of imatinib to interact with Pgp as a sub-
trate in our model, we performed the Rho-123 efﬂux assay. As
emonstrated in Fig. 4A, imatinib was able to interact with Pgp,
odulating Pgp activity and causing an increase in Rho-123 dye
oncentration inside the cells in relation to cells not treated with
matinib. This result shows that imatinib interacts with Pgp with
ore afﬁnity than Rho-123, competing for the same the active site.rch 37 (2013) 1350– 1358 1353
However, imatinib Pgp modulation is discrete when compared with
CSA, a well-known Pgp modulator.
3.5. Pgp activity as imatinib resistance factor
To verify whether imatinib resistance of Lucena cells was only
due to Pgp overexpression, we  modulated Pgp activity using VRP,
a potent Pgp modulator. As observed in Fig. 4B, the modulation of
Pgp activity by VRP evidently increased the percentage of apop-
totic cells (annexin V+/PI+) in Lucena cell line when treated with
imatinib at 1 M for 48 h (p = 0.002). However, when a high con-
centration of imatinib (5 M)  was tested, no alteration in apoptosis
induction was  observed in cells treated with VRP, indicating that
imatinib resistance due to Pgp overexpression is overcome when
high doses of this drug is offered. Nevertheless, when we compared
the percentage of apoptotic cells of Lucena treated with imatinib
plus VRP with K562 cells, we observe that the modulation/blockage
of Pgp activity was not sufﬁcient to overcome imatinib resistance
and induce the same values of apoptosis as observed in K562 cells.
This result suggests that there are others resistance factors beyond
Pgp overexpression in Lucena cell line responsible for imatinib
resistance.
3.6. Effects of imatinib on Pgp expression in CML  cell lines
Since we veriﬁed that imatinib is able to interact with Pgp,
modulating its function, we  analyzed the capability of this drug
in changing Pgp expression in a Pgp+ cell line. As shown in Fig. 5A,
imatinib was able to increase the expression of Pgp in Lucena cells,
especially at the concentration of 5 M (p = 0.007). An increment of
three times in Pgp expression was observed at this concentration.
However, no signiﬁcant change was observed in K562.
As previously described by our group [19], imatinib was also
able to induce a signiﬁcant increase in Pgp mRNA expression in
Lucena but not in K562 cell line. On the opposite, the basal level
of Pgp mRNA expression in K562 cells was  decreased by imatinib,
indicating that imatinib causes different responses in Pgp protein
expressing and non-Pgp protein expressing cells.
3.7. Modulation of XIAP and survivin expressions induced by
imatinib in CML cell lines
We  next investigated XIAP and survivin expressions after imat-
inib treatment in CML  cell lines. In K562 cells, imatinib treatment
did not alter signiﬁcantly the levels of XIAP mRNA (Fig. 5B), while at
protein level, XIAP was downregulated after imatinib treatment at
1 M and 5 M for 24 h (Fig. 5D). Interestingly, in Lucena cells, the
opposite effect was observed: imatinib signiﬁcantly upregulated
XIAP mRNA expression (Fig. 5B), that was followed by a discrete
increment in XIAP protein expression at the concentration of 5 M
(Figs. 5D and 6). In relation to survivin expression, both cell lines
showed a signiﬁcant decrease in mRNA (Fig. 5C) and protein expres-
sions (Fig. 5D).
3.8. Knockdown of XIAP by siRNA sensitizes K562 and Lucena
cells to imatinib
Since we  veriﬁed that imatinib was  able to increase signiﬁcantly
the levels of XIAP mRNA expression in Lucena cells, we  transfected
K562 and Lucena cell lines with XIAP siRNA in order to verify the
inﬂuence of XIAP overexpression in imatinib resistance. As demon-
strated in Fig. 6, the knockdown of XIAP in both cell lines with
siRNA decreased XIAP expression. Furthermore, the treatment with
imatinib for more 24 h intensiﬁed XIAP downregulation in both
cell lines, especially at 5 M.  This decrement of XIAP expression
was  accompanied by an increase in the levels of cleaved caspase-3
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Fig. 3. Induction of apoptosis by imatinib in K562 (Pgp−) and Lucena (Pgp+) cell lines. (A) Cells were treated with imatinib (0.5, 1.0 and 5.0 M) for 24 h, 48 h and 72 h, stained
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. DiscussionXIAP overexpression has been related to poor prognosis in some
ematological malignancies [5]. However, the expression of XIAP
n CML  has not been well explored yet, and little is known about its
ole in the evolution of this disease, drug resistance or prognosis.
ig. 4. Imatinib is a substrate for P-glycoprotein (Pgp) in Lucena (Pgp+) cells. (A) Imatinib 
erformed and analyzed by ﬂow cytometry. This ﬁgure is representative of 5 independen
ctivity  increases apoptosis in Lucena cells after imatinib exposure. K562 (Pgp-negative
IM  1) and 5 M (IM 5) in presence or absence of verapamil (VRP) at 50 M.  Annexin V st
ercentage of annexin V positive cells in relation to control of three independent exper
ucena cells treated only with IM 1 and treated with IM 1 + VRP (p = 0.002). Student’s t testest was performed. *p < 0.05; **p < 0.001. (B) Activation of caspase-3 by imatinib in
matinib at 1.0 M (IM 1) and 5.0 M (IM 5) for 24 h. Western blot was performed.
Based on that, the present study evaluated the expression of XIAP
protein in CML  samples. Our results have shown that 50% of CML
samples exhibited high levels of XIAP expression and the majority
of samples from patients at accelerated/blastic phases demon-
strated this characteristic. Quintás-Cardama et al. [21] found, by
reverse phase protein array, an elevated expression of XIAP in
patients at accelerated and blastic phases when compared with
those in chronic phase of CML. However, due to the wide variation
of XIAP expression among these groups, we found no statistical
association between XIAP expression and CML phases. Besides, we
also did not observe a differential expression of XIAP in relation
acts as a modulator of Pgp activity. The Rhodamine-123 (Rho-123) efﬂux assay was
t experiments. CSA = cyclosporin A. IM = imatinib. (B) Modulation of P-glycoprotein
) and Lucena (Pgp-positive) cell lines were treated with imatinib for 48 h at 1 M
aining assay was performed. Data represents the mean + standard deviation of the
iments. Arrows show the difference in the percentage of apoptotic cells between
t was  performed.
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Fig. 5. Effects of imatinib in P-glycoprotein (Pgp), XIAP and Survivin expressions in K562 (Pgp−) and Lucena (Pgp+) cell lines. K562 and Lucena cell lines were treated with
imatinib  (IM) at 1.0 and 5 M for 24 h. (A) Pgp expression was  evaluated by ﬂow cytometry. RFI = ratio of ﬂuorescence intensity. Pgp expression increment refers to the
number of times that treated cells had their mean of ﬂuorescence intensity increased or not in relation to control. M ± SD, n = 3. (B) Relative XIAP mRNA expression in K562
and  Lucena cell lines. Real time qRT-PCR was performed. M ± SD, n = 3 (C) Relative survivin mRNA expression in K562 and Lucena cell lines. Real time qRT-PCR was performed.
M  ± SD, n = 3. (D) XIAP and survivin proteins expressions in K562 and Lucena cell lines. Western blot was performed. XIAP and survivin levels are expressed through XIAP or
survivin/-actin densitometric ratio normalized in relation to control. Figure is representative of three independent experiments. *p < 0.05.
Fig. 6. Downregulation of XIAP expression in K562 (Pgp−) and Lucena (Pgp+) cell lines by siRNA and response to imatinib. Analysis of XIAP and cleaved-caspase 3 expressions
after  K562 and Lucena cells transfection with scramble siRNA or XIAP siRNA for 24 h and subsequent imatinib treatment at 1 M (IM 1) and 5 M (IM 5) for 24 h. Western blot
was  performed. XIAP and cleaved-caspase-3 levels are expressed through XIAP or cleaved-caspase-3/-actin densitometric ratio normalized in relation to control. Figure is
representative of four independent experiments.
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o Sokal risk groups, suggesting that XIAP could not be associ-
ted to prognosis. Nevertheless, the role of XIAP as a factor of poor
rognosis is controversial, and it seems to be cancer-type-speciﬁc
18,22–25].
Seeger et al. [26] demonstrated that XIAP overexpression alone
s not sufﬁcient to cause drug resistance. Actually, the acquisition of
DR phenotype is multifactorial, and many molecules are involved.
ome reports have been suggesting a relationship between IAPs and
gp expressions [12,27–29]. In a previous study, our group reported
 signiﬁcant correlation between survivin and Pgp expressions in
ML  samples from patients in late chronic phase, suggesting that
ML  treatment might contribute to MDR  phenotype appearance
13]. In another work, we also veriﬁed that high doses of vincristine,
 Pgp substrate, resulted in the increment of Pgp and survivin
xpressions in K562 cells, and it was associated with low rates of
poptosis [14]. Moreover, the same authors observed that Pgp and
urvivin were co-localized in the cytoplasm, reinforcing the idea
hat there is a functional relationship between these proteins [14].
nterestingly, in the present study, we veriﬁed a positive correla-
ion between XIAP and Pgp expressions in CML  samples, showing
hat XIAP overexpression was accompanied by Pgp overexpression.
evertheless, neither the expression of XIAP or Pgp was  related to
gp function. In fact, it has been suggested that Pgp also confers
esistance to apoptosis not related to its drug efﬂux pump activity,
nhibiting the activation of caspases from different stimuli such as
ltra-violet, serum starvation and chemotherapeutic drugs [30,31].
Even though the relationship between XIAP and Pgp expressions
as not related to CML  evolution or prognosis, this observation led
s to think whether cells with high co-expression of XIAP and Pgp
ould have a poor response to imatinib in relation to cells without
his phenotype, since several reports have shown imatinib resis-
ance as a consequence of Pgp overexpression [32–36]. Hence, we
valuated the action of imatinib in two cell lines, K562 (Pgp−) and
ucena (Pgp+), and we veriﬁed that Lucena was shown to be less
ensitive than K562, especially when treated with at the lowest
matinib concentration. In agreement with our results, Correa et al.
ecently showed that Lucena cells were resistant to imatinib in rela-
ion to K562 and presented an IC50 5-fold greater than K562 cells
37].
We  also observed that imatinib was able to interact with Pgp
uggesting that this drug acts as a modulator agent and, conse-
uently, a substrate of Pgp. Hence, imatinib can be extruded by Pgp
or extracellular medium. According to Dohse et al., imatinib acts as
 substrate or as a modulator of Pgp depending on its concentration
33]. They discussed that in the leukemic stem cell niche, imatinib is
t low concentration, and the substrate phenotype could dominate
33]. In this work, we showed that imatinib acted as a weak modu-
ator when compared with CSA. These results are in agreement with
he study of Mukai et al. that showed that imatinib is less efﬁciently
ransported by Pgp than vincristine [38]. In order to verify whether
matinib resistance in Lucena cells was due to Pgp overexpress-
on exclusively, we blocked its activity with VRP. Here we observed
hat the blockage of Pgp activity provided an increment of apoptosis
aused by imatinib, when administrated at clinical concentration
1 M),  in Lucena but not in K562 cells. Correa et al. also observed
imilar results. Seca et al. [39] observed a modulation of imatinib
esistance in K562Dox cells (that overexpress Pgp) when VRP was
ncubated with imatinib causing a signiﬁcant decrease in the per-
entage of viable cells, being this response similar to observed to
ownregulation of Pgp by siRNA. Nevertheless, the blockage of Pgp
ctivity was not sufﬁcient to become Lucena as sensitive as K562
ells to imatinib suggesting that might be others mechanisms of
matinib resistance in Lucena cell line.
An interesting point of the present study was to observe that
ell lines with different patterns of MDR  phenotype (presence or
bsence of Pgp overexpression) had different responses to imatinibrch 37 (2013) 1350– 1358
when Pgp and XIAP expressions were analyzed. Surprisingly, in
Lucena cells, imatinib increased more their Pgp overexpression,
while K562 cells kept their Pgp protein expression undetectable.
Recent reports have shown not only that drugs classically known
as Pgp inductors, such as vincristine, doxorubicin, and etoposide,
are able to increase the expression of Pgp but also that imatinib
upregulates Pgp expression attributed to cellular mechanism of
defense in response to stress caused by the drug [40,41]. However,
cell lines that are continuously exposed to imatinib are capable of
increasing Pgp expression at mRNA and protein levels and keeping
this phenotype [40,41]. Moreover, patients who had received imat-
inib showed signiﬁcantly increased Pgp-positive cells, suggesting
that imatinib is capable of selecting leukemic stem cells that are
characterized by Pgp expression [36]. Interestingly, we observed
that the increment of Pgp mRNA and protein expressions in Lucena
observed after imatinib treatment was  accompanied by an increase
of XIAP expression, especially at high concentration. On the other
hand, K562 cells had their levels of XIAP mRNA and protein signif-
icantly decreased after imatinib treatment. In fact, some articles
have shown that imatinib is able to decrease XIAP expression in
K562 cells and it is related to apoptosis induction [9,11,42]. A possi-
ble explanation for the decrement in XIAP expression in K562 cells
is that imatinib is activating the mitochondrial pathway of apopto-
sis induction, releasing cytocrome c and Smac from mitochondria
that is able to link to XIAP driving this protein to degradation
through ubiquitin-proteosomal complex. This situation drives
the cells to capase-3 activation, as observed in this article and in
other studies for K562 cell line, inducing apoptosis [9,11]. How-
ever, Lucena cells presented a lower activation of caspase-3 and,
consequently, a resistance to imatinib-induced apoptosis when
compared to K562, suggesting that XIAP is really acting as an anti-
apoptotic protein in Lucena cells that survived to imatinib injury.
In fact, knockdown of XIAP by siRNA facilitated the downregulation
of XIAP expression and activation of caspase-3 by imatinib in both
cell lines. However, once more, Lucena exhibited a more resistant
proﬁle to imatinib when compared to K562 cells. Our results show
that neither the blockage of Pgp activity nor the knockdown of
XIAP alone are sufﬁcient to overcome imatinib resistance in Lucena
cell line. Seca et al. also observed that the downregulation of Pgp
or XIAP alone by siRNA caused similar decrease in percentage of
viable cells in relation to control. However, when the simultaneous
downregulation of Pgp and XIAP was evaluated a more pronounced
effect of imatinib was  observed [39]. Our results together with
literature suggest that a downregulation of both XIAP and Pgp is
necessary to overcome imatinib resistance in MDR  cells.
Differently observed for XIAP, imatinib signiﬁcantly decreased
survivin expression at mRNA and protein levels in both cell lines,
showing that the IAPs XIAP and survivin have different responses
to imatinib stimulus. In addition, imatinib enhanced the MDR  phe-
notype (Pgp and XIAP overexpressions) in a cell line that presents
an MDR  proﬁle and decreased the levels of these proteins in a
non-MDR cell line. This result suggests that there is a relationship
between Pgp and XIAP and the interaction of imatinib with Pgp
at plasma membrane could shoot a different pathway in Lucena
cell line activating the transcription of Pgp and XIAP mRNAs. How-
ever, the relationship between IAPs and Pgp expression remains
unclear. In fact, the induction of MDR  phenotype in MCF7/ADR
breast cancer cells led to an increase of survivin and XIAP expres-
sion in relation to its parental cell line [29,43]. However, the up-
or down-regulation of XIAP or survivin expression did not alter
Pgp expression, and no direct interaction, such as protein-protein
linkage, was  observed between XIAP or survivin and Pgp [43]. Nev-
ertheless, Liu et al. demonstrated that survivin transcription is
regulated by Pgp activity through PI3K/Akt pathway and the inhi-
bition of Pgp with adriamycin decreases the activity of survivin
promoter transcription [29].
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Some studies have reported that some factors or pathways, such
s p53, NFB, and Ras/Raf signaling pathway, may  simultaneously
egulate the expressions of IAPs and Pgp [44–46]. Perhaps, K562
nd Lucena have different proﬁles of protein expression beyond
gp, and these differences could be important for differential imat-
nib response. In fact, proteomic analysis identiﬁed 36 differentially
xpressed proteins related to cell cycle and proliferation, signaling
ransduction, metabolism, stress response, etc. [43], but none of
hem were directly linked with factors or pathways previously
escribed as Pgp or IAPs regulators.
. Conclusions
Our study shows that imatinib induces an increment of MDR
henotype of CML  cells by the selection of Pgphigh/XIAPhigh cells or
y the induction of transcription, effects that can contribute to drug
esistance. In addition, the positive correlation observed between
IAP and Pgp in CML  samples might contribute to clinical imatinib
esistance. However, further studies are necessary to understand
he association of these proteins in CML  cells.
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